patient recruitment, Healthy Volunteers

Medikine, Inc.

MDK-703-101 is a single ascending dose study, to determine the safety, tolerability, and PK/PD of MDK-703 in healthy adult subjects.

Healthy Volunteers

MDK-703 or Placebo

Phase 1

Study Type :	Interventional
Estimated Enrollment :	26 participants
Masking :	Single
Primary Purpose :	Basic Science
Official Title :	A Phase 1, Randomized, Placebo-controlled, Single-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MDK-703 in Healthy Adult Volunteers
Actual Study Start Date :	June 30, 2022
Estimated Primary Completion Date :	December 28, 2022
Estimated Study Completion Date :	December 28, 2022

Arm	Intervention/treatment
Experimental: Cohort 1 Single injection of MDK-703 (dose level 1) or matching placebo	Biological: MDK-703 or Placebo
Experimental: Cohort 2 Single injection of MDK-703 (dose level 2) or matching placebo	Biological: MDK-703 or Placebo
Experimental: Cohort 3 Single injection of MDK-703 (dose level 3) or matching placebo	Biological: MDK-703 or Placebo

Inclusion Criteria

1. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or ECGs.

Exclusion Criteria

1. Significant history or clinical manifestation of any metabolic, autoimmune, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, or psychiatric disorder.

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Not yet recruiting

Medikine Clinical Site

Herston, Queensland, Australia,